Go back to 1918 and private rentals accounted for 76% of the housing market

Bayer-Temasek, Shire-Allergan, Aviva, FCA-Barclays, Buffett-USG, IBM, Netflix and Facebook

Japanese tech group just keeps confounding expectations

Jes Staley has been judged by the regulator but jury is still out on his performance as chief

US tobacco group has a problem with older smokers

Botox maker eyes return to acquisition trail, but a tie-up would not add much value

A $1bn buyback reflects the asset manager’s share price frustration

Adding a few sequins to a fading strategy has not arrested the decline in sales

An imbroglio that companies, lawmakers and regulators must resolve

The price can only get heavier but can it hit $3,000 per tonne?

There are benefits to maintaining status quo with local partners

Investors could, in theory, put a spoke in the plan to quit London

A simplified regime does not mean higher shareholder returns

Social network sails close to the wind with facial recognition plans

Choking off copycat drugs is a bad strategy

Group beats earnings estimates but beyond the jargon questions over the cloud remain

M&A disappointed even as the rest of the firm prospered

Sovereign wealth fund opts to seed German life sciences group for next spurt of growth

Retailer’s success looks all the more remarkable when held up against Sports Direct

Sanctions are bad news for the Chinese telecoms group but its rivals have little to gain

Equity cushion just became fatter after streaming service’s quarterly results

Knauf’s interest is perfectly timed as Berkshire wants out of building products group

To back the bid, investors must believe it can cut costs and promote faster growth

Market’s guillotine mechanism likely to lessen retired supremo’s chances of success